Results. In skeletally immature mice, HDAd-IL1Ra prevented development of cartilage damage, osteophytes, and synovitis. In skeletally immature and mature mice, treatment with HDAd-interleukin-1 receptor antagonist post-OA induction resulted in improved-albeit not significantly-cartilage status assessed histologically and significantly increased cartilage volume, cartilage surface, and bone surface covered by cartilage as assessed by micro-CT. Fewer osteophytes were observed in HDAd-IL-1Ra-treated skeletally immature mice. Synovitis was not affected in skeletally immature or mature mice. HDAd-IL-1Ra protected against disease-induced thermal hyperalgesia in skeletally mature mice. In the horse OA model, HDAd-IL1Ra therapy significantly improved lameness parameters, indicating efficient symptomatic treatment. Moreover, macroscopically and histologically assessed cartilage and synovial membrane parameters were significantly improved, suggesting disease-modifying efficacy.
Conclusion. These data from OA models in small and large animals demonstrated safe symptomatic and disease-modifying treatment with an HDAd-expressing IL-1Ra. Furthermore, this study establishes HDAd as a vector for joint gene therapy.
Osteoarthritis (OA) is the most common joint disorder and the leading cause of disability in the aged population. Currently, there are no available drugs with a disease-modifying effect that could positively influence the ongoing cartilage degeneration. Thus, because medication is limited to management of the symptoms of OA, many patients progress to development of endstage disease due to continuous cartilage degeneration. There is therefore a large unmet medical need for novel therapeutic approaches that can be used to sustainably treat the symptoms of OA and are disease-modifying.
OA is characterized by progressive cartilage degeneration, subchondral bone remodeling, and chronic in- flammation. One of the key players in OA is interleukin-1 (IL-1), which is up-regulated in cartilage and synovial tissue and can be correlated with osteoarthritic changes (1) (2) (3) . IL-1 amplifies inflammation in OA by inducing other inflammatory mediators (4) and directly contributes to cartilage matrix loss by increasing cartilage catabolism through up-regulation of extracellular proteolytic enzymes while simultaneously suppressing cartilage anabolism through down-regulation of collagen and proteoglycan synthesis (1) . IL-1 is also suspected to be one of the key mediators of pain in OA, which is one of the major symptoms and the most common reason for patients to consult a physician (5, 6) . Therefore, the IL-1 pathway may be an ideal target for OA therapy because blockade of this pathway could potentially be used to both treat symptoms and modify disease.
One of the most efficient inhibitors of the IL-1 pathway is the endogenous IL-1 receptor antagonist (IL-1Ra), which competes with IL-1 for IL-1R binding without inducing signal transduction (7) . Recombinant IL-1Ra is available as the drug anakinra, which has been evaluated in a randomized, double-blind, placebocontrolled clinical trial in knee OA patients (8) . In that study, patients treated with a single intraarticular injection of anakinra exhibited significantly improved pain scores compared with placebo-treated patients at an early time point. However, 4 weeks after injection there was no longer a significant difference between the active treatment and placebo groups. These findings suggested that IL-1Ra is effective against OA; however, based on the limited bioavailability of the IL-1Ra protein in the joint, the effect was not sustained (8) . With a synoviocyte-targeted gene therapy approach, which leads to long-term IL-1Ra production within the joint, the bioavailability issue could be overcome.
In multiple small and large animal models, helper-dependent adenoviral vectors (HDAds), also known as high-capacity or gutless adenoviral vectors, have been shown to mediate long-term transgene expression and exhibit significantly less adaptive immunogenicity compared with first-generation adenoviral vectors, as HDAds do not express viral proteins (9) (10) (11) . In a previous study we have shown that in joints, HDAds achieve stable gene expression for >1 year after intraarticular injection (12) . Furthermore, we have demonstrated that HDAds transduce synoviocytes in mice after intraarticular injection, with greater efficiency than the widely used adenoassociated viruses (AAVs) (12) . Therefore, HDAds seem to be well suited for joint-directed gene therapy, and we chose to utilize these vectors for IL-1Ra gene therapy for local administration in OA. In this study, we have shown that HDAd-IL-1Ra vectors efficiently treat the symptoms of OA and are disease-modifying in small (mouse) and large (horse) animal models.
MATERIALS AND METHODS
HDAds. HDAd-murine IL-1Ra (HDAd-mIL-1Ra) and HDAd-equine IL-1Ra (HDAd-eqIL-1Ra) carry the murine and equine variants, respectively, of IL-1Ra complementary DNA (cDNA) driven by the inflammation-inducible NFjB endothelial leukocyte adhesion molecule (ELAM) promoter. The control vector HDAd-GFP contains the green fluorescent protein (GFP) cDNA under the control of the same NF-jB ELAM promoter. HDAd genomic plasmids pD28 containing NF-jB ELAM promoter and murine or equine IL1Ra, or GFP were constructed, and HDAd viruses were rescued using AdNG163 helper virus as described by Palmer and Ng (13) . Large-scale preparations of these vectors were produced as described by Suzuki et al (14) . HDAd preparations were confirmed to be endotoxin free.
Mouse cruciate ligament transection model. Cruciate ligament transection (CLT) surgery was performed on knee joints of 8-week-old and 12-week-old male FVB/N mice as previously described (15) . For histologic assessment, knee joints were decalcified in 14% or 10% EDTA for 5 or 10 days, respectively, at 4°C and then embedded in paraffin. Sections were cut at 6 lm and stained with Safranin O and fast green using standard protocols. For assessments of cartilage damage, sections from the lateral compartment were scored according to the Osteoarthritis Research Society International (OARSI) histologic grading system (16) and scores for the tibia and femur were summed. The medial compartment was not scored as in this model the severity of displacement on the medial side is typically too great to be scored with the OARSI system. To assess for the presence of synovitis, sections from the lateral compartment were scored using a 3-point scale. Osteophytes were scored as being either present in or absent from histologic sections and expressed as the percentage of joints with osteophytes in relation to all analyzed joints. For phase-contrast micro-computed tomography (micro-CT) imaging, whole knee joints were prepared, scanned, and evaluated as described previously (15) .
In 12-week-old mice, hot plate nociception analysis was performed to assess thermal hyperalgesia. On the day of assessment, mice were transferred to the room of analysis and allowed to acclimate for at least 30 minutes prior to studies being performed at 50 Lux and 60 dB. Each mouse was then placed on the hot plate (Columbus Instruments) at 55°C and observed for a maximum of 45 seconds. The latency period to hind limb flicking and hind limb licking or jumping was recorded as minor and major response time, respectively. Horse osteochondral fragment model. These studies were conducted at Cornell University and approved by the Institutional Animal Care and Use Committee.
In the middle carpal joint of 1 randomly chosen forelimb skeletally mature (3-6 years) thoroughbred racehorses, a radial carpal bone osteochondral fragment was surgically formed to induce OA. A 10-mm curved gouge was used to separate the fragment from the dorsal aspect of the radial carpal bone, and a motorized burr was used to expand the fracture bed to 15 mm. Debris was deliberately retained in the joint to induce degenerative changes. The middle carpal joint in the opposite limb was sham operated, but no fracture formation was performed. Five days after surgery (day 0), the fragmented joint was injected with 2 9 10 11 viral particles (vp) HDAd-eqIL-1Ra (low dose), 2 9 10 12 vp HDAd-eqIL-1Ra (high dose), or phosphate buffered saline (PBS) as a control (n = 4 per treatment group). Horses were exercised with a rigorous treadmill program 5 days per week.
Serial lameness examination, limb swelling assessment, and synovial fluid analysis for total protein, nucleated cell count, and differential cell count, as well as enzyme-linked immunosorbent assay for equine IL-1Ra (R&D Systems) were performed multiple times over a period of up to 72 days, after which the horses were killed and tissue obtained for assessment. Blood was collected at multiple time points for complete blood cell count and serum chemistry analysis. Lameness evident at walk, range of motion, lameness after flexion, and joint effusion were assessed daily for the first week after HDAd injection and weekly thereafter.
Horses were killed by pentobarbital overdose 72 days after HDAd injection. The carpi from both fore limbs were disarticulated from the remaining tissues, and gross examination of the carpal joint surfaces and synovial membrane was performed by 2 observers. Gross necropsy examination was performed by a board-certified pathologist. Samples of articular cartilage and osteochondral sections were collected and fixed in 4% paraformaldehyde prior to paraffin embedding. Osteochondral samples were decalcified in citrate buffered formic acid. Cartilage and osteochondral sections were cut and stained with hematoxylin and eosin (H&E)-toluidine blue to assess proteoglycan content, or by immunohistochemistry for type II collagen. Sections were evaluated under blinded conditions. Biodistribution quantitative polymerase chain reaction (PCR). DNA from tissue (~100 mg) was extracted using proteinase K and phenol-chloroform and diluted in water to a concentration of 20 ng/ll. DNA from serum samples (~200 ll) was extracted using a ChargeSwitch gDNA 1ml Serum Kit (ThermoFisher Scientific) and diluted in water to a concentration of 10 ng/ml. One microliter of each sample was used for PCR.
Quantitative real-time PCR was performed using a LightCycler v2 and FastStart DNA Master SYBR Green (Roche). The following primers binding the HDAd-eqIL-1Ra genome were used: 5 0 -TCTGAATAATTTTGTGTTACTCATAGCGCG-3 0 and 5 0 -CCCATAAGCTCCTTTTAACTTGTTAAAGTC-3 0 . Annealing temperature was 60°C.
Statistical analysis. In mouse experiments, groups were compared by one-way analysis of variance followed by Tukey multiple comparisons test. Group differences in the scored data from the horse experiments (lameness assessment, macroscopic cartilage and synovial membrane analysis, and histologic evaluation) were tested by nonparametric Kruskal-Wallis analysis of variance with follow-up pairwise comparison. Observer scores were averaged for statistical testing. Statistical analysis was performed using Prism 6 (GraphPad) or Statistix 9 (Analytical Software). For all tests, P values less than 0.05 were considered significant.
RESULTS
HDAd-mIL-1Ra prevents and treats OA in a mouse model. To test the efficacy of an HDAd expressing murine IL-1Ra under the control of the inflammation- Figure 1 . Histologic scoring after presurgical treatment of skeletally immature mice with a helper-dependent adenoviral vector expressing murine interleukin-1 receptor antagonist (HDAd-mIL-1Ra) in a model of severe posttraumatic osteoarthritis (OA). Two days prior to cruciate ligament transection surgery, 8-week-old male mice were injected intraarticularly with HDAd-mIL-1Ra, a control vector containing green fluorescent protein (GFP), or phosphate buffered saline (PBS). Six weeks later, joints were collected and processed for Safranin O-fast green histochemical staining (n = 10 knees from 5 mice). To assess histologic signs of OA pathogenesis, tissue sections from the lateral compartment were analyzed for cartilage damage (A) (n = 5-8 per group), synovitis (B) (n = 9-10 per group), and the presence of osteophytes (percentage of joints with osteophytes in relation to all analyzed joints) (C) (n = 9-10 per group). HDAd-mIL-1Ra-treated joints had significantly lower (better) Osteoarthritis Research Society International (OARSI) scores compared with HDAd-GFP-treated controls and PBS-injected joints, with trends toward reductions in synovitis and osteophyte formation. In A and B, circles represent individual joints; bars show the mean AE SD. * = P < 0.05.
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inducible promoter NF-jB (HDAd-mIL-1Ra) in OA in vivo, we used the mouse CLT model recently developed in our laboratory (15) . HDAd-mIL-1Ra (1 9 10 8 vp), the GFP-expressing control vector HDAd-GFP (1 9 10 8 vp), or PBS was injected intraarticularly into 8-week-old mice (10 knees from 5 mice), and 2 days later OA was induced by CLT. Six weeks after surgery, mice were killed and OA severity was assessed by OARSI histologic grading by an independent observer, who was blinded with regard to intervention. Joints treated with HDAd-mIL-1Ra had significantly lower OARSI scores, i.e., less severe OA, compared with joints treated with HDAd-GFP or PBS (n = 5-8 per group) ( Figure 1A and Supplementary Figure 1 , on the Arthritis & Rheumatology web site at http://onlinelib rary.wiley.com/doi/10.1002/art.40668/abstract). The average synovitis score of HDAd-mIL-1Ra-treated joints appeared to be lower compared with the HDAd-GFP and PBS groups (n = 9-10 per group), although the difference was not statistically significant ( Figure 1B) . Furthermore, fewer osteophytes were observed in the HDAd-mIL-1Ra group compared with the HDAd-GFP and PBS groups (n = 9-10 per group) ( Figure 1C ). These data suggest that HDAd-mIL-1Ra prevents the development of OA in this model. Figure 2 . Histologic scoring and phase-contrast micro-computed tomography (micro-CT) results after postsurgical treatment of skeletally immature mice with HDAd-mIL-1Ra in a model of severe posttraumatic OA. Cruciate ligament transection surgery was performed on 8-week-old male mice to induce OA, followed by intraarticular delivery of HDAd-mIL-1Ra, HDAd-GFP (control), or PBS 2 weeks after surgery. Six weeks later, joints were collected and processed for Safranin O-fast green histochemical staining (n = 10 joints from 8 mice) or phase-contrast micro-CT analysis (n = 5). To assess histologic signs of OA pathogenesis, tissue sections from the lateral compartment were analyzed for cartilage damage (A) (n = 6-8 per group), synovitis (B) (n = 7-10 per group), and the presence of osteophytes (percentage of joints with osteophytes in relation to all analyzed joints) (C) (n = 3-5 per group). To quantify cartilage volume (D), cartilage surface (E), and bone surface covered by cartilage (F), wholejoint phase-contrast micro-CT was performed on separately prepared joints. The mean OARSI score in the HDAd-mIL-1Ra-treated group was slightly lower compared with the HDAd-GFP-and PBS-treated groups, but the difference was not statistically significant. Synovitis was unaffected by HDAd-mIL-1Ra treatment. Osteophytes were not detected in HDAd-mIL-1Ra-treated joints but were detected in 33.3% and 66.7% of samples from the HDAd-GFP and PBS groups, respectively. Phase-contrast micro-CT analysis of cartilage volume, cartilage surface, and bone surface covered by cartilage revealed significantly higher values in HDAd-mIL-1Ra-treated joints compared with HDAd-GFP-and PBS-injected joints, while there was no significant difference between HDAd-mIL-1Ra-treated and sham-operated joints. In A, B, and D-F, circles represent individual joints; bars show the mean AE SD. * = P < 0.05. See Figure 1 for other definitions.
Next, we evaluated whether HDAd-mIL-1Ra can efficiently treat established OA in 8-week-old mice. CLT was performed, 2 weeks later HDAd-mIL-1Ra (1 9 10 8 vp), HDAd-GFP (1910 8 vp), or PBS was injected, and a further 6 weeks later joints were analyzed by OARSI grading (n = 10 knees from 8 mice per group) and phasecontrast micro-CT imaging (n = 5 per group). The mean OARSI score was lower in HDAd-mIL-1Ra-injected joints compared with HDAd-GFP-treated and PBSinjected joints, although the differences were not statistically significant (n = 6-8 per group) (Figure 2A and Supplementary Figure 2 [http://onlinelibrary.wiley.com/ doi/10.1002/art.40668/abstract]). All treatment groups (HDAd-mIL-1Ra, HDAd-GFP, and PBS) had significantly worse OARSI scores compared with shamoperated (healthy) joints from age-matched mice. No difference in the synovitis score was observed between treatment groups, all of which had higher scores than the sham group (n = 7-10 per group) ( Figure 2B ). No osteophytes were detected in the HDAd-mIL-1Ra-injected joints, while 33.3% and 66.7% of the HDAd-GFP and PBS samples, respectively, had osteophytes (n = 3-5 per group) ( Figure 2C ). Using phase-contrast micro-CT imaging, we showed that the HDAd-mIL-1Ra-treated joints had significantly higher cartilage volume, cartilage surface area, and bone area covered by cartilage compared with HDAd-GFP-and PBS-treated joints (Figures 2D-F) . While these parameters were all significantly lower in the HDAd-GFP and PBS groups compared with the sham-operated group, no significant difference was observed between HDAd-mIL-1Ra-treated and shamoperated joints.
To evaluate the efficacy of the treatment in mice that were skeletally mature, we repeated the above experiments in 12-week-old mice. Three days after surgery, mice were injected with HDAd-mIL-1Ra (1 9 10 9 vp), HDAd-GFP (1 9 10 9 vp), or PBS and assessed 2 months later for cartilage damage, synovitis, and osteophytes by histologic analysis and phase-contrast micro-CT imaging, as well as for pain by hot plate nociceptive assay. The mean histologic score for cartilage damage in HDAd-mIL-1Ra-treated mice tended to be lower compared with that in the HDAd-GFP and PBS groups (n = 12-16 mice per group), but the differences were not statistically significant (Figure 3A and Supplementary Figure 3 , on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/d oi/10.1002/art.40668/abstract). All treatment groups had significantly higher scores compared with the sham-operated group. No difference was seen in the synovitis scores of the HDAd-mIL-1Ra, HDAd-GFP, and PBS groups, while all of these groups had significantly higher scores compared with the sham group ( Figure 3B) . Additionally, the number of osteophytes did not differ between the HDAd-mIL-1Ra, HDAd-GFP, and PBS groups (Figure 3C) . Phase-contrast micro-CT revealed significantly higher cartilage volume in HDAd-mIL-1Ra-treated joints compared with joints injected with HDAd-GFP, but there was no significant difference between the HDAdmIL-1Ra group and the PBS group ( Figure 3D) or the sham-operated group. Bone surface covered by cartilage was significantly higher in HDAd-mIL-1Ra-treated joints compared with both the HDAd-GFP and the PBS groups ( Figure 3E ). In the hot plate nociception analysis, HDAd-mIL-1Ra treatment led to a significantly higher minor response time compared with HDAd-GFP and PBS treatment ( Figure 3F ). The minor response time of HDAd-mIL-1Ra-treated mice was not significantly different from that of healthy mice in the sham group, indicating protection from thermal hyperalgesia. Major response times in the hot plate nociception analysis of HDAd-mIL-1Ra-treated mice were higher on average than in the HDAd-GFP and PBS groups, but the differences did not reach statistical significance ( Figure 3G) .
Expression of equine IL-1Ra by HDAd-eqIL-1Ra in vitro and in vivo, dependent on inflammatory status. Expression and functionality of the inflammation-inducible promoter system of an HDAd expressing equine IL-1Ra (HDAd-eqIL-1Ra) was confirmed in vitro (Supplementary Figure 4 , on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40668/ abstract). In a dose-escalation experiment, 4 different doses of HDAd-eqIL-1Ra (2 9 10 11 vp, 6 9 10 11 vp, 2 9 10 12 vp, and 6 9 10 12 vp) were injected into the carpal and metacarpophalangeal joints of 1 horse. IL-1Ra concentrations in the synovial fluid were high on the first 2 days (Supplementary Figure 5 , http://onlinelibrary.wiley. com/doi/10.1002/art.40668/abstract). Administration of a nonsteroidal antiinflammatory drug (NSAID) (phenylbutazone, 1 gm twice daily on days 2-5) reduced the IL-1Ra concentration in the synovial fluid, but levels increased again when NSAID treatment was stopped (day 7). On day 90, inflammation was induced by injection of lipopolysaccharide (0.125 ng) into 2 of the joints (previously injected with 2 9 10 11 and 6 9 10 12 vp HDAdeqIL-1Ra), which led to reactivation of IL-1Ra expression 2 days later, confirming sustained IL-1Ra expression in vivo.
Intraarticular delivery of HDAd-eqIL-1Ra is well tolerated in horses. OA was induced by surgical formation of an osteochondral fragment in 1 carpal joint per horse. Five days later (day 0), HDAd-eqIL-1Ra at a dose of 2 9 10 11 vp (low dose) or 2 9 10 12 vp (high dose) or PBS was injected intraarticularly (n = 4 per group). Since we had shown in 3 mouse OA experiments that the control vector HDAd-GFP has no significant effect, we omitted this group in the horse experiment for ethical and cost reasons. The injection site showed no signs of inflammation or other adverse reactions. A mild and transient elevation of white blood cell counts in the synovial fluid, which returned to normal after 14 days, was noted in the low-dose group; whereas no significant change occurred in the high-dose group ( Figure 4A) . Compared with earlier studies with a firstgeneration adenovirus expressing equine IL-1Ra in horses (17) , the white blood cell reaction in our study using an HDAd was much lower. Synovial fluid total protein concentration in both the low-and high-dose HDAd-eqIL-1Ra groups did not change more than in the PBS group ( Figure 4B ). Gross pathologic assessment of the liver, spleen, heart, and ovaries (where present) Figure 3 . Histologic scoring, phase-contrast micro-computed tomography (micro-CT) results, and pain assessment after postsurgical treatment of skeletally mature mice with HDAd-mIL-1Ra in a model of severe posttraumatic OA. Cruciate ligament transection surgery was performed on 12-week-old skeletally mature mice to induce OA, followed by intraarticular delivery of HDAd-mIL-1Ra, HDAd-GFP (control), or PBS 72 hours later. Eight weeks postsurgery, joints were collected and processed for Safranin O-fast green histochemical staining or phase-contrast micro-CT analysis. To assess histologic signs of OA pathogenesis, tissue sections from the lateral compartment were analyzed for cartilage damage (A), synovitis (B), and the presence of osteophytes (percentage of joints with osteophytes in relation to all analyzed joints) (C) (n = 12-16 mice per group). To quantify cartilage volume (D) and bone surface covered by cartilage (E), whole-joint phase-contrast micro-CT was performed on separately prepared joints (n = 7-9 mice per group). To assess effects of IL-1Ra gene therapy on OA-associated pain, mice were evaluated using the hot plate nociceptive assay, in which response time to hind paw flick (minor response) (F) and hind paw lick or jump (major response) (G) was quantified (n = 12-16 mice per group). In this model, HDAd-mIL-1Ra treatment did not affect histologic signs of cartilage damage, synovitis, or osteophytes. Phase-contrast micro-CT analysis showed significantly higher values for cartilage volume in the HDAd-mIL-1Ra group compared with the HDAd-GFP group. Bone surface covered by cartilage was also significantly greater in HDAd-mIL-1Ra-injected joints compared with PBS-and HDAd-GFP-injected joints. Hot plate nociception analysis revealed that HDAd-mIL-1Ra protected against increased thermal hyperalgesia as evidenced by a significantly longer hind paw flick response time compared with the HDAd-GFP and PBS groups. Response times to hind paw lick or jump for hot plate nociception analysis were on average higher in the HDAd-mIL-Ra group compared with the HDAd-GFP and PBS groups, but the differences were not significant. In A, B, and D-G, circles represent individual joints; bars show the mean AE SD. * = P < 0.05. See Figure 1 for other definitions.
at the end of the experiment (72 days after injection) showed no pathologic changes. Moreover, no significant levels of HDAd-eqIL-1Ra vector genomes were found in the liver, spleen, heart, or ovaries by quantitative PCR (Supplementary Table 1 , on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10. 1002/art.40668/abstract), indicating that the virus did not disseminate from the joint. This conclusion is further supported by the fact that levels of HDAd-eqIL-1Ra vector genomes were not increased in the serum on days 21 or 72, and HDAd-eqIL-1Ra vector genome levels in the feces from animals in the high-dose group were not increased, above those in controls.
Reduction of OA symptoms with HDAd-eqIL-1Ra treatment in a horse model. Equine IL-1Ra protein levels in the synovial fluid were~20 ng/ml 4 days after injection of low-or high-dose HDAd-eqIL-1Ra. These levels gradually declined during the course of the experiment, until they were~1 ng/ml and 0.1 ng/ml in the low-and high-dose groups, respectively, on day 72 ( Figure 4C ). The clinical parameters lameness, range of motion, pain on flexion, and effusion were all improved (lower scores) by HDAd-eqIL-1Ra treatment compared with PBS treatment, although no dose-dependency was seen (Figure 4D) . Specifically, the average lameness score assessed on the American Association of Equine Practitioners (AAEP) 0-5 scale (0 = no lameness, 5 = severe lameness) was 58% lower in the low-dose HDAd-eqIL-1Ra group compared with the PBS group (P = 0051), while the highdose group had a statistically significant 67% improvement in the average score (P = 0.029). Range of motion assessed on a 0-4 scale (0 = no reduction, 4 = >75% reduction) was completely restored in the low-dose HDAd-eqIL-1Ra group (P = 0.029), while in the 
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high-dose group it was reduced by 38% compared with the PBS group (P = 0.229). Videos of the range of motion assessment of representative animals from the PBS group (score 3) and the low-dose HDAd-eqIL-1Ra group (score 0) are shown in Supplementary Videos 1 and 2, on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40668/abstract). The average score for lameness after flexion assessed on the AAEP 0-5 scale was significantly lower in the lowdose HDAd-eqIL-1Ra group (71%; P = 0.031) and highdose HDAd-eqIL-1Ra group (57%; P = 0.039) compared with the PBS group. Also, effusion assessed on a scale of 0-4 (0 = no effusion, 4 = marked effusion) was significantly improved in the low-dose HDAd-eqIL-1Ra group (44%; P = 0.029) and high-dose HDAd-eqIL-1Ra group (33%; P = 0.049) compared with the PBS group.
Improved synovial membrane status in osteoarthritic joints of horses with HDAd-eqIL-1Ra treatment. The horses were killed on day 72, and the synovial membrane was evaluated macroscopically ( Figure 5A ). In both Figure 5 . Synovial membrane status of the osteoarthritic joints of HDAd-eqIL-1Ra-injected horses. HDAd-eqIL-1Ra at a low dose (2 9 10 11 vp) or high dose (2 9 10 12 vp) was injected intraarticularly into horse carpal joints with osteochondral fragments, and horses were killed 72 days later (n = 4 per group). Macroscopic evaluation of the synovial membrane showed that the color of the HDAd-eqIL-1Ra-treated joints was similar to the color of sham-operated joints, whereas PBS-treated control joints appeared more reddish (A and B) . Arrowheads indicate location of osteochondral fragmentation. The synovial membrane of HDAd-eqIL-1Ra-treated joints was also significantly less thick compared with that of PBS-treated controls (B). Values are the mean AE SEM. Hematoxylin and eosin staining of synovial membrane from the dorsal aspect of the middle carpal joint indicated less infiltration of inflammatory cells and less synovial hyperplasia in the HDAd-eqIL-1Ra-treated joints compared with PBS-treated joints (C). Original magnification 9 100. * = P < 0.05. See Figure 4 for definitions. Figure 6 . Macroscopic and histologic evaluation of cartilage from the osteoarthritic joints of HDAd-eqIL-1Ra-injected horses. HDAd-eqIL-1Ra at a low dose (2 9 10 11 vp) or high dose (2 9 10 12 vp) was injected intraarticularly into horse carpal joints with osteochondral fragments, and horses were killed 72 days later (n = 4 per group). Macroscopic evaluation of the joint surface showed less fibrillation (lower scores) in the intermediate carpal bone (CI), radial carpal bone (CR), third facet of the intermediate carpal bone (C3IF), and third facet of the radial carpal bone (C3RF) regions of the joints in the HDAd-eqIL-1Ra-treated joints compared with PBS-treated control joints, and the total fibrillation score for all regions was significantly lower (better) in the HDAd-eqIL-1Ra groups compared with PBS-treated controls (A). Hematoxylin and eosin (H&E)-staining of cartilage sections revealed better-healed cartilage defects in HDAd-eqIL-1Ra-treated joints compared with PBS controls (B) (Middle row shows radial carpal bone with a healing fracture [top] and opposing third carpal bone [bottom] [original magnification 9 2]; upper and lower rows show higher-magnification views [original magnification 9 5] of radial carpal bone and third carpal bone.) Type II collagen staining was more intense in HDAd-eqIL-1Ra-treated joints compared with PBS-treated controls (original magnification × 5; bar = 300 lm) (C). Histologic sections stained with H&E or toluidine blue or for type II collagen were evaluated for 9 different osteoarthritis-related parameters: cartilage fibrillation (CF), polarized collagen fiber pattern (PCFP), tidemark duplication (TD), chondrocyte density (CD), chondrocyte cloning (CC), subchondral bone erosions (SBE), osteophytes (Oste), proteoglycan content (% toluidine stained [TS]), and type II collagen content (C2C) (D). All parameters were improved (lower scores) in HDAd-eqIL-1Ra-treated joints compared with PBS controls, and the total histology score was significantly lower (better) in the HDAd-eqIL-1Ra groups compared with the PBS group. Values are the mean AE SEM. * = P < 0.05. See Figure 4 for other definitions.
the low-and high-dose HDAd-eqIL-1Ra groups the color of the synovial membrane (assessed on a scale of 0-4: 0 = tan/normal, 4 = red/black) was more similar to the color of sham-operated (normal healthy) joints than was the color of PBS-treated joints (Figures 5A and B) . Furthermore, the synovial membrane from the HDAd-eqIL-1Ra groups was significantly less thick (0-4 scale: 0 = normal, 4 = fibrotic) compared with that from the PBS group (Figure 5B) , indicating a decrease in synovitis. Microscopic evaluation of H&E-stained samples of the synovial membrane confirmed the macroscopic findings by demonstrating less inflammatory cell infiltration and less synovial hyperplasia in the HDAd-eqIL-1Ra-treated groups compared with the PBS-treated group ( Figure 5C ).
Improved cartilage status in osteoarthritic joints of horses with HDAd-eqIL-1Ra treatment. The cartilage surface was macroscopically evaluated in 4 different areas: intermediate carpal bone, radial carpal bone (the site where the osteochondral defect was created), the intermediate facet of the third carpal bone, and the radial facet of the third carpal bone. In all 4 areas, the low-and high-dose HDAd-eqIL-1Ra-treated joints had less severe cartilage fibrillation compared with those of PBS-treated controls (assessed on a scale of 0-4: 0 = normal, 4 = eburnation), and the total fibrillation scores (for all regions combined) in the HDAd-eqIL-1Ra groups were significantly lower compared with the PBS group ( Figure 6A ).
Histologic sections exhibited better healing of the osteochondral fragment of the radial carpal bone (Figure 6B ) and better cartilage status of the opposing third carpal bone in both HDAd-eqIL-1Ra groups compared with PBS-treated joints. Type II collagen staining was more intense and more evenly distributed in the HDAd-eqIL1Ra groups compared with the PBS group ( Figure 6C ). To quantify histologic changes, stained sections were scored on a scale of 0-3 or 0-4 (0 = normal/healthy status, 3/4 = most severe status) by a pathologist who was blinded with regard to treatment. Less cartilage fibrillation was observed in both the low-and high-dose HDAd-eqIL-1Ra groups, together with better-organized collagen fiber polarization, compared with the PBS group ( Figure 6D ). Less tidemark duplication was seen in the low-dose HDAd-eqIL-1Ra group compared with the PBS group. Chondrocyte density was comparable with that in healthy cartilage, and less chondrocyte cloning was seen in both HDAd-eqIL-1Ra groups compared with the PBS group. Furthermore, there were fewer subchondral bone erosions and fewer osteophytes in both the low-and high-dose HDAd-eqIL-Ra groups compared with the PBS group. Both HDAd-eqIL-1Ra groups also had higher proteoglycan and type II collagen content (lower scores) compared with PBS controls. For some of the histologic parameters, low-and high-dose HDAd-eqIL-1Ra seemed to have differently strong effects, although there were no statistically significant differences between the 2 groups. The total histologic scores in the low-and high-dose HDAd-eqIL-1Ra groups were significantly better (lower scores) compared with those in the PBS control group and were not significantly different from those in sham-operated controls.
DISCUSSION
One of the major challenges in the treatment of chronic joint diseases such as OA is the necessity to provide sustained bioavailability of a therapeutic agent within the joint. Systemically administered drugs cannot sufficiently reach the synovial space, and intraarticularly injected agents are cleared from the joint fluid rapidly by the lymphatic system, which severely compromises their bioavailability (18) . Gene therapy may offer an ideal approach for treatment of OA because local application can lead to long-term production of a therapeutic protein within the joint, resulting in high, sustained intraarticular concentrations.
Herein we report that intraarticular, synoviocytetargeted HDAd-mediated IL-1Ra gene therapy results in symptomatic and disease-modifying treatment of OA in small and large animal models. In order to work with a homologous model, we constructed an HDAd expressing murine IL-1Ra and tested this vector in mice that had undergone CLT. In younger, skeletally immature mice, HDAd-mIL-1Ra efficiently prevented and treated surgically induced OA as shown by improved histologic scores and fewer osteophytes compared with treatment with control vector (HDAd-GFP) or PBS, although synovitis was not affected (Figures 1 and 2A-C) . However, in older mice, histologic and osteophyte scores in HDAd-mIL-1Ra-treated mice were not significantly different from those in controls ( Figures 3A and C) , due to the more aggressive nature of the posttraumatic disease. At the same time, phase-contrast micro-CT imaging demonstrated significantly higher cartilage volume, cartilage surface area, and bone surface covered by cartilage in HDAd-mIL-1Ra-treated joints compared with controls in both skeletally immature mice ( Figures 2D-F) and skeletally mature mice ( Figures 3D and E) postsurgery. The discrepancy between the histologic scores and the phase-contrast micro-CT results in the older cohort is understandable given the increased sensitivity of the latter. Interestingly, despite the severe damage caused by surgery in the skeletally mature mice, HDAdmIL-1Ra significantly protected against thermal hyperalgesia compared with that observed in controls. Taken together, these data suggest that HDAd-mediated IL-1Ra gene expression has a disease-modifying effect and provides symptomatic relief from pain in the CLT mouse model of posttraumatic OA.
Next, we sought to test this gene therapy approach in large animals and chose the equine carpal osteochondral fragment model. Since horses and humans have similarly sized joints, comparable cartilage thickness, and similar subchondral bone structure, the equine model is highly relevant for OA in humans (17, (19) (20) (21) . In this model, we tested the efficacy and toxicity of 2 different doses of an HDAd expressing equine IL-1Ra after a single intraarticular injection. No injection site reactions and no changes in blood chemistry, gross pathology, or general behavior were observed in any of the horses, indicating good tolerability and absence of overt adverse events. Both doses led to IL-1Ra concentrations in the synovial fluid over the 72-day period of the experiment that had earlier been shown to be therapeutic (17, 22, 23) . Marked improvements in lameness, range of motion, lameness after flexion, and effusion were seen with HDAd-eqIL1Ra at both doses compared with control ( Figure 4D ). The effect correlated with IL-1Ra levels in the synovial fluid at this time point but was not dose dependent. These results indicate efficient management of OA-associated pain, which is particularly important since OA-associated chronic pain significantly affects patients' quality of life and is the most common reason for patients to consult their physicians. We also demonstrated significantly better cartilage status in HDAd-eqIL-1Ra-treated joints compared with control joints (Figure 6 ), which is consistent with the results of previous studies demonstrating a positive effect on OA cartilage after blocking of the IL-1 pathway (17, 23, 24) . Moreover, HDAd-eqIL-1Ra resulted in significantly improved status of the synovial membrane ( Figure 5 ) and subchondral bone, as well as fewer osteophytes ( Figure 6D ) compared with controls, although no significant dose-dependency was seen with the 2 tested doses. Since OA is considered a "whole joint disease" involving not only cartilage but also subchondral bone, synovium, and ligament, these data are of particular importance.
The murine CLT surgical model of OA used in this study mimics severe OA progression and end-stage disease as seen in human patients following traumatic joint injury. Specifically, in this mouse model, transection of both cruciate ligaments leads to complete anteroposterior destabilization of the knee and subsequent OA development. We have shown that in this mouse model, cartilage degeneration progresses continuously with great severity (15), similar to findings in patients with OA caused by cruciate ligament tears. Further, by performing surgeries on mice of 2 different ages, we were able to assess the efficacy of HDAd-IL-1Ra gene therapy in disease of varying and increasing severity. In the horse model, the osteochondral defect, which is created initially, has some self-healing capacity. However, lameness and cartilage status do not return to normal in untreated controls during the observation period (17, (19) (20) (21) , which is comparable to findings in patients with OA due to cartilage defects. These 2 models, therefore, likely represent 2 different, clinically relevant types of OA, both of which we were able to treat with our IL-1Ra gene therapy approach.
In this study we chose to use HDAd as a gene therapy vector. Frisbie et al demonstrated that a firstgeneration adenovirus expressing IL-1Ra treats OA efficiently (17) . However, IL-1Ra expression was lost after 5 weeks. HDAds, which lack all viral genes, have been shown to elicit a significantly lower adaptive immune response compared with first-generation adenoviral vectors (25) and to achieve multi-year expression in various animal models (9) (10) (11) . Recently we showed that HDAds with a constitutive promoter mediated stable gene expression after intraarticular injection for the entire follow-up period of >1 year in mice (12) . Furthermore, herein we have demonstrated markedly less white blood cell influx in synovial fluid with the use of HDAds (Figure 4A ) compared with the study by Frisbie et al with a first-generation adenovirus using the same dose (17) . AAVs have also been evaluated for joint gene therapy (26) (27) (28) . In a direct comparison we observed that HDAds have higher transduction efficiency in joints compared with several AAV serotypes (12) , which explains why in most studies higher doses of AAV were used for joint gene therapy (28, 29) compared with the HDAd doses in this study. Therefore, HDAds may be ideally suited for joint-directed gene therapy.
In conclusion, we have shown that an HDAd expressing IL-1Ra efficiently treats the symptoms of OA and exerts disease-modifying activity in relevant small and large animal models. In the horse model, we assessed 2 doses but did not see a consistently better effect with the higher dose, indicating that the low dose could be used to treat OA in joints of the size assessed in this study (i.e., equine carpal joints and human knee joints). We did not observe any adverse events or toxicity with either of the doses, indicating that both the low dose, which may be optimal for joints of this size, as well as a 10-fold higher dose are safe. The studies described herein lay the foundation for the clinical development of HDAds expressing IL-1Ra for treatment of OA in horses, humans, and other species. Furthermore, this work establishes HDAd as a gene therapy platform for the treatment of OA and other joint disorders.
